Uveitis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Uveitis - Pipeline Review, H2 2018’, provides an overview of the Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Uveitis

- The report reviews pipeline therapeutics for Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Uveitis therapeutics and enlists all their major and minor projects

- The report assesses Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Uveitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Uveitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aciont Inc

Aldeyra Therapeutics Inc

Alvotech Iceland

Apitope International NV

Bristol-Myers Squibb Co

Clearside BioMedical Inc

Coherus BioSciences Inc

Elasmogen Ltd

Enzo Biochem Inc

EyeGate ...

Aciont Inc

Aldeyra Therapeutics Inc

Alvotech Iceland

Apitope International NV

Bristol-Myers Squibb Co

Clearside BioMedical Inc

Coherus BioSciences Inc

Elasmogen Ltd

Enzo Biochem Inc

EyeGate Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

F. Hoffmann-La Roche Ltd

Fresenius SE & Co KGaA

Galapagos NV

HanAll Biopharma Co Ltd

Idera Pharmaceuticals Inc

Johnson & Johnson

Kv1.3 Therapeutics

Midatech Pharma Plc

Mitotech SA

Nemus Bioscience Inc

Novartis AG

OncoNOx ApS

Ophthotech Corp

Orchid Pharma Ltd

Palatin Technologies Inc

Panoptes Pharma GesmbH

Re-Pharm Ltd

Sandoz International GmbH

Santen Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Uveitis – Overview 6

Uveitis – Therapeutics Development 7

Uveitis – Therapeutics Assessment 17

Uveitis – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 5

Uveitis – Overview 6

Uveitis – Therapeutics Development 7

Uveitis – Therapeutics Assessment 17

Uveitis – Companies Involved in Therapeutics Development 25

Uveitis – Drug Profiles 40

Uveitis – Dormant Projects 177

Uveitis – Discontinued Products 181

Uveitis – Product Development Milestones 182

Appendix 200

List of Tables

List of Tables

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Uveitis – Pipeline by Aciont Inc, H2 2018

Uveitis – Pipeline by Aldeyra Therapeutics Inc, H2 2018

Uveitis – Pipeline by Alvotech Iceland, H2 2018

Uveitis – Pipeline by Apitope International NV, H2 2018

Uveitis – Pipeline by Bristol-Myers Squibb Co, H2 2018

Uveitis – Pipeline by Clearside BioMedical Inc, H2 2018

Uveitis – Pipeline by Coherus BioSciences Inc, H2 2018

Uveitis – Pipeline by Elasmogen Ltd, H2 2018

Uveitis – Pipeline by Enzo Biochem Inc, H2 2018

Uveitis – Pipeline by EyeGate Pharmaceuticals Inc, H2 2018

Uveitis – Pipeline by EyePoint Pharmaceuticals Inc, H2 2018

Uveitis – Pipeline by Eyevensys SAS, H2 2018

Uveitis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Uveitis – Pipeline by Fresenius SE & Co KGaA, H2 2018

Uveitis – Pipeline by Galapagos NV, H2 2018

Uveitis – Pipeline by HanAll Biopharma Co Ltd, H2 2018

Uveitis – Pipeline by Idera Pharmaceuticals Inc, H2 2018

Uveitis – Pipeline by Johnson & Johnson, H2 2018

Uveitis – Pipeline by Kv1.3 Therapeutics, H2 2018

Uveitis – Pipeline by Midatech Pharma Plc, H2 2018

Uveitis – Pipeline by Mitotech SA, H2 2018

Uveitis – Pipeline by Nemus Bioscience Inc, H2 2018

Uveitis – Pipeline by Novartis AG, H2 2018

Uveitis – Pipeline by OncoNOx ApS, H2 2018

Uveitis – Pipeline by Ophthotech Corp, H2 2018

Uveitis – Pipeline by Orchid Pharma Ltd, H2 2018

Uveitis – Pipeline by Palatin Technologies Inc, H2 2018

Uveitis – Pipeline by Panoptes Pharma GesmbH, H2 2018

Uveitis – Pipeline by Re-Pharm Ltd, H2 2018

Uveitis – Pipeline by Sandoz International GmbH, H2 2018

Uveitis – Pipeline by Santen Pharmaceutical Co Ltd, H2 2018

Uveitis – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Uveitis – Dormant Projects, H2 2018

Uveitis – Dormant Projects, H2 2018 (Contd..1), H2 2018

Uveitis – Dormant Projects, H2 2018 (Contd..2), H2 2018

Uveitis – Dormant Projects, H2 2018 (Contd..3), H2 2018

Uveitis – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Uveitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports